Does the media prefer SLN or AARD?

In the previous week, Aardvark Therapeutics had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 3 mentions for Silence Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.72 beat Silence Therapeutics' score of 0.62 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABEO or AARD more profitable?

Abeona Therapeutics' return on equity of -53.98% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -53.98% -38.52% Aardvark Therapeutics N/A -61.71% -56.29%

Does the media prefer ABEO or AARD?

In the previous week, Abeona Therapeutics had 6 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 12 mentions for Abeona Therapeutics and 6 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.72 beat Abeona Therapeutics' score of -0.63 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AMRN or AARD?

In the previous week, Aardvark Therapeutics had 3 more articles in the media than Amarin. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 3 mentions for Amarin. Amarin's average media sentiment score of 0.89 beat Aardvark Therapeutics' score of 0.72 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CLLS or AARD?

In the previous week, Aardvark Therapeutics had 2 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 4 mentions for Cellectis. Aardvark Therapeutics' average media sentiment score of 0.72 beat Cellectis' score of 0.38 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aardvark Therapeutics (AARD) Competitors

$3.94 +0.04 (+1.00%)

As of 10:45 AM Eastern

Compare

AARD vs. SLN, ABEO, AMRN, CLLS, and SIGA

Should you buy Aardvark Therapeutics stock or one of its competitors? MarketBeat compares Aardvark Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aardvark Therapeutics include Silence Therapeutics (SLN), Abeona Therapeutics (ABEO), Amarin (AMRN), Cellectis (CLLS), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry.

How does Aardvark Therapeutics compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

In the previous week, Aardvark Therapeutics had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 3 mentions for Silence Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.72 beat Silence Therapeutics' score of 0.62 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aardvark Therapeutics has lower revenue, but higher earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	584.17	-$88.61M	-$1.59	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

98.7% of Silence Therapeutics shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Silence Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 4.47, meaning that its stock price is 347% more volatile than the broader market.

Silence Therapeutics currently has a consensus price target of $55.00, indicating a potential upside of 694.22%. Aardvark Therapeutics has a consensus price target of $19.70, indicating a potential upside of 400.13%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Aardvark Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Aardvark Therapeutics' return on equity of -61.71% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

Summary

Aardvark Therapeutics beats Silence Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Abeona Therapeutics has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	55.18	$71.18M	$0.97	5.81
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Abeona Therapeutics' return on equity of -53.98% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

In the previous week, Abeona Therapeutics had 6 more articles in the media than Aardvark Therapeutics. MarketBeat recorded 12 mentions for Abeona Therapeutics and 6 mentions for Aardvark Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.72 beat Abeona Therapeutics' score of -0.63 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abeona Therapeutics presently has a consensus target price of $19.00, indicating a potential upside of 237.18%. Aardvark Therapeutics has a consensus target price of $19.70, indicating a potential upside of 400.13%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Abeona Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 4.47, meaning that its stock price is 347% more volatile than the broader market.

80.6% of Abeona Therapeutics shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Abeona Therapeutics beats Aardvark Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Amarin?

Amarin (NASDAQ:AMRN) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

In the previous week, Aardvark Therapeutics had 3 more articles in the media than Amarin. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 3 mentions for Amarin. Amarin's average media sentiment score of 0.89 beat Aardvark Therapeutics' score of 0.72 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amarin has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 4.47, indicating that its stock price is 347% more volatile than the broader market.

Amarin has higher revenue and earnings than Aardvark Therapeutics. Amarin is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.50	-$38.80M	-$0.65	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

22.3% of Amarin shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Amarin presently has a consensus target price of $12.00, indicating a potential downside of 21.59%. Aardvark Therapeutics has a consensus target price of $19.70, indicating a potential upside of 400.13%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Aardvark Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

Summary

Amarin and Aardvark Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Cellectis?

Cellectis (NASDAQ:CLLS) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Cellectis has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 4.47, indicating that its stock price is 347% more volatile than the broader market.

63.9% of Cellectis shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aardvark Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Aardvark Therapeutics' return on equity of -61.71% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

In the previous week, Aardvark Therapeutics had 2 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 4 mentions for Cellectis. Aardvark Therapeutics' average media sentiment score of 0.72 beat Cellectis' score of 0.38 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectis presently has a consensus price target of $7.00, suggesting a potential upside of 123.64%. Aardvark Therapeutics has a consensus price target of $19.70, suggesting a potential upside of 400.13%. Given Aardvark Therapeutics' higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Aardvark Therapeutics has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.95	-$67.59M	-$0.67	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Summary

Aardvark Therapeutics beats Cellectis on 9 of the 15 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Siga Technologies?

Aardvark Therapeutics (NASDAQ:AARD) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Siga Technologies has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Siga Technologies	$94.57M	3.27	$23.28M	$0.27	15.95

Siga Technologies has a net margin of 21.58% compared to Aardvark Therapeutics' net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Siga Technologies	21.58%	10.60%	8.94%

Aardvark Therapeutics has a beta of 4.47, meaning that its stock price is 347% more volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

In the previous week, Aardvark Therapeutics had 5 more articles in the media than Siga Technologies. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 1.87 beat Aardvark Therapeutics' score of 0.72 indicating that Siga Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Aardvark Therapeutics	Positive
Siga Technologies	Very Positive

55.4% of Siga Technologies shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aardvark Therapeutics currently has a consensus target price of $19.70, suggesting a potential upside of 400.13%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aardvark Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Siga Technologies beats Aardvark Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Aardvark Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AARD vs. The Competition

Export

Metric	Aardvark Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$84.86M	$3.39B	$6.49B	$12.31B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-1.21	20.05	24.05	24.76
Price / Sales	N/A	325.48	542.61	168.32
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.80	8.16	10.69	6.90
Net Income	-$57.59M	$23.89M	$3.57B	$337.45M
7 Day Performance	9.72%	3.66%	1.56%	2.84%
1 Month Performance	-13.81%	1.69%	2.49%	4.78%
1 Year Performance	-63.32%	46.95%	26.51%	33.08%

Aardvark Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AARD Aardvark Therapeutics	4.2249 of 5 stars	$3.94 +1.0%	$19.70 +400.1%	-63.7%	$84.86M	N/A	N/A	18	Gap Down
SLN Silence Therapeutics	2.5669 of 5 stars	$6.69 +0.1%	$55.00 +722.1%	+25.5%	$315.53M	$560K	N/A	100
ABEO Abeona Therapeutics	2.8698 of 5 stars	$5.53 flat	$19.00 +243.6%	-10.2%	$315.18M	$5.82M	5.70	90
AMRN Amarin	0.4795 of 5 stars	$15.24 +2.3%	$12.00 -21.3%	+15.0%	$312.44M	$213.65M	N/A	360
CLLS Cellectis	2.4769 of 5 stars	$3.09 flat	$7.00 +126.5%	+132.3%	$310.05M	$79.59M	N/A	290	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AARD) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aardvark Therapeutics (AARD) Competitors

AARD vs. SLN, ABEO, AMRN, CLLS, and SIGA

How does Aardvark Therapeutics compare to Silence Therapeutics?

Summary

How does Aardvark Therapeutics compare to Abeona Therapeutics?

Summary

How does Aardvark Therapeutics compare to Amarin?

Summary

How does Aardvark Therapeutics compare to Cellectis?

Summary

How does Aardvark Therapeutics compare to Siga Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aardvark Therapeutics (AARD) Competitors

AARD vs. SLN, ABEO, AMRN, CLLS, and SIGA

How does Aardvark Therapeutics compare to Silence Therapeutics?

Does the media prefer SLN or AARD?

Which has higher valuation and earnings, SLN or AARD?

Do insiders and institutionals believe in SLN or AARD?

Which has more risk & volatility, SLN or AARD?

Do analysts recommend SLN or AARD?

Is SLN or AARD more profitable?

Summary

How does Aardvark Therapeutics compare to Abeona Therapeutics?

Which has preferable earnings & valuation, ABEO or AARD?

Is ABEO or AARD more profitable?

Does the media prefer ABEO or AARD?

Do analysts recommend ABEO or AARD?

Which has more risk and volatility, ABEO or AARD?

Do institutionals & insiders believe in ABEO or AARD?

Summary

How does Aardvark Therapeutics compare to Amarin?

Does the media refer more to AMRN or AARD?

Which has more volatility and risk, AMRN or AARD?

Which has higher earnings and valuation, AMRN or AARD?

Do insiders & institutionals have more ownership in AMRN or AARD?

Do analysts recommend AMRN or AARD?

Is AMRN or AARD more profitable?

Summary

How does Aardvark Therapeutics compare to Cellectis?

Which has more risk and volatility, CLLS or AARD?

Do insiders and institutionals have more ownership in CLLS or AARD?

Is CLLS or AARD more profitable?

Does the media prefer CLLS or AARD?

Do analysts rate CLLS or AARD?

Which has stronger earnings and valuation, CLLS or AARD?

Summary

How does Aardvark Therapeutics compare to Siga Technologies?

Which has higher valuation & earnings, AARD or SIGA?

Is AARD or SIGA more profitable?

Which has more volatility & risk, AARD or SIGA?

Does the media favor AARD or SIGA?

Do institutionals & insiders hold more shares of AARD or SIGA?

Do analysts prefer AARD or SIGA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools